← 返回

解析结直肠癌免疫微环境串扰中的信号通路以克服免疫治疗耐药性

英文原题:Unraveling Signaling Pathways in Immune Microenvironment Crosstalk to Overcome Immunotherapy Resistance in Colorectal Cancer.

查看英文原题

Unraveling Signaling Pathways in Immune Microenvironment Crosstalk to Overcome Immunotherapy Resistance in Colorectal Cancer.

PubMed 2026/02/13(内容时间) Hum Mutat Q4 · IF 1.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

作为全球癌症相关死亡的主要原因,结直肠癌(CRC)在微卫星高度不稳定(MSI-H)之外的情况下,对免疫治疗在很大程度上仍然难治。这种有限的疗效主要源于肿瘤微环境(TME)内复杂的串扰,其促进了免疫抑制和耐药。本综述分析了失调通路——如 PD-1/PD-L1、cGAS/STING、Notch 和细胞因子信号传导——对 CRC 中 T 细胞、B 细胞、巨噬细胞、树突状细胞和 NK 细胞功能状态的影响。我们探讨了这些通路如何支撑免疫逃逸、T 细胞耗竭以及先天免疫细胞的促肿瘤极化等关键过程,从而为肿瘤生长和对检查点抑制剂的耐药营造有利的微环境。讨论还涵盖了新兴生物标志物和创新策略,包括靶向关键信号节点的联合治疗,以重编程免疫格局。对这些免疫调节通路更深入的机制理解,对于开发有效治疗以克服耐药并改善患者预后至关重要。

展开英文摘要原文

As a major cause of cancer-related death globally, colorectal cancer (CRC) remains largely refractory to immunotherapy outside the context of microsatellite instability-high (MSI-H). This limited efficacy stems largely from the complex crosstalk within the tumor microenvironment (TME), which fosters immunosuppression and resistance.

Our review analyzes the impact of dysregulated pathways-such as PD-1/PD-L1, cGAS/STING, Notch, and cytokine signaling-on the functional states of T cells, B cells, macrophages, dendritic cells, and NK cells in CRC.

We investigate how these pathways underpin critical processes such as immune evasion, T cell exhaustion, and the protumor polarization of innate immune cells, thereby fostering a permissive niche for tumor growth and resistance to checkpoint inhibitors.

The discussion also covers emerging biomarkers and innovative strategies, including combination therapies targeting pivotal signaling nodes, to reprogram the immune landscape. A deeper mechanistic understanding of these immunoregulatory pathways is essential for developing effective treatments to overcome resistance and improve patient prognosis.

论文信息

作者
Zhang H、Shao J、Zhao T、Wang Y、Shao L、Zhu H、Liu J、Zhang L
单位
Department of Clinical Laboratory Medicine, Affiliated Tumor Hospital of Nantong University and Nantong Tumor Hospital, Nantong, Jiangsu, China.China
文献类型
综述
期刊
Human mutation2026
原文标识
PubMed 41693728 · DOI 10.1155/humu/2744471